The NSCLC group demonstrated significantly higher levels of serum BMP2 than the control group. The median serum levels of BMP2 in the advanced stage group (stage IIIb or IV) were significantly elevated compared with those of the localized stage group (stages I, II, and IIIa). This evidence concerns the gene BMP2 and non-small cell lung carcinoma.